Reckitt Benckiser Group plc (OTCMKTS:RBGLY) Given Consensus Recommendation of “Buy” by Brokerages

Reckitt Benckiser Group plc (OTCMKTS:RBGLY) has earned a consensus recommendation of “Buy” from the seven research firms that are currently covering the company, MarketBeat.com reports. Two research analysts have rated the stock with a hold rating, one has assigned a buy rating and four have assigned a strong buy rating to the company.

Several analysts recently weighed in on the company. HSBC upgraded Reckitt Benckiser Group from a “hold” rating to a “buy” rating in a research note on Wednesday, December 11th. Sanford C. Bernstein downgraded shares of Reckitt Benckiser Group from a “strong-buy” rating to a “hold” rating in a research note on Monday, November 4th. Hsbc Global Res upgraded shares of Reckitt Benckiser Group from a “hold” rating to a “strong-buy” rating in a research note on Wednesday, December 11th. Finally, Barclays upgraded shares of Reckitt Benckiser Group to a “strong-buy” rating in a research report on Friday, October 4th.

Reckitt Benckiser Group Trading Up 2.3 %

Shares of OTCMKTS RBGLY opened at $13.35 on Friday. The business’s 50-day simple moving average is $12.23 and its 200-day simple moving average is $11.97. The company has a debt-to-equity ratio of 0.97, a current ratio of 0.69 and a quick ratio of 0.47. Reckitt Benckiser Group has a 52 week low of $10.24 and a 52 week high of $15.03.

Reckitt Benckiser Group Company Profile

Reckitt Benckiser Group plc manufactures and sells health, hygiene, and nutrition products worldwide. It offers acne treatment creams, facial washes, and cleansing pads; germ protection products; condoms; heartburn and indigestion solutions; joints health products; chest congestion, cough, and sinus remedies; brain health products; migraine-headaches and rheumatic pain products; sore throat medications; and hair removal products under the Airborne, Clearasil, Dettol, Durex, Gaviscon, Move Free, Neuriva, Nurofen, Mucinex, Strepsils, and Veet brands.